New FDA Approved Drug Combo Offers Hope For Patients
6 days ago · Understanding HER+ Breast Cancer A new FDA-approved treatment for HER2-positive metastatic breast cancer—trastuzumab deruxtecan (Enhertu) in combination with …
FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer
Dec 15, 2025 · It is a type of targeted therapy drug known as a monoclonal antibody. References "FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or …
FDA Greenlights Enhertu‑Pertuzumab Combo as First‑Line Therapy …
Dec 16, 2025 · The U.S. Food and Drug Administration has granted a breakthrough approval for a combination therapy designed to treat adults with unresectable or metastatic HER2-positive …
Enhertu plus pertuzumab approved in the US as first new …
Dec 15, 2025 · AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult …
T-DXd Wins First-Line Indication for HER2+ Breast Cancer
Dec 16, 2025 · FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or metastatic HER2-positive breast cancer.
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki With …
On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) in combination with pertuzumab for the first-line treatment of …
Enhertu/Perjeta Combo Earns FDA Approval in Advanced HER2+ Breast Cancer
Dec 15, 2025 · The treatment combination of Enhertu and Perjeta was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer.
FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2 ...
Dec 15, 2025 · The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki; AstraZeneca and Daiichi Sankyo) plus Perjeta (pertuzumab) for the first-line treatment of adults with …
ENHERTU® Plus Pertuzumab Approved in the U.S. as First
Dec 15, 2025 · ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic …
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic …
Dec 15, 2025 · The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.